These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


194 related items for PubMed ID: 35731991

  • 1. Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors.
    Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ.
    J Clin Oncol; 2022 Aug 10; 40(23):2539-2545. PubMed ID: 35731991
    [Abstract] [Full Text] [Related]

  • 2. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
    Lassman AB.
    CNS Oncol; 2015 Aug 10; 4(5):341-6. PubMed ID: 26544062
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.
    J Clin Oncol; 2013 Jan 20; 31(3):344-50. PubMed ID: 23071237
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Webre C, Shonka N, Smith L, Liu D, De Groot J.
    Anticancer Res; 2015 Oct 20; 35(10):5467-72. PubMed ID: 26408710
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.
    Cancer; 2005 Feb 15; 103(4):802-9. PubMed ID: 15637687
    [Abstract] [Full Text] [Related]

  • 8. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B.
    Ann Oncol; 2003 Apr 15; 14(4):599-602. PubMed ID: 12649108
    [Abstract] [Full Text] [Related]

  • 9. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V, Dehais C, Martin E, Carpentier C, Uro-Coste E, Figarella-Branger D, Bronniman C, Pouessel D, Ciron DL, Ducray F, Moyal EC, Network P.
    Oncologist; 2021 May 15; 26(5):e838-e846. PubMed ID: 33524191
    [Abstract] [Full Text] [Related]

  • 10. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S, Talari G, Rosenfeld M, Guo J, Villano JL.
    Cochrane Database Syst Rev; 2017 Jul 26; 7(7):CD011773. PubMed ID: 28744879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1147-52. PubMed ID: 15001257
    [Abstract] [Full Text] [Related]

  • 13. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ.
    J Neurooncol; 2015 Jan 15; 121(2):365-72. PubMed ID: 25344884
    [Abstract] [Full Text] [Related]

  • 14. Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
    Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoorn M, Wesseling P, Hoang-Xuan K, Van den Bent M, Sanson M.
    Cancer; 2011 Jul 01; 117(13):3014-26. PubMed ID: 21246521
    [Abstract] [Full Text] [Related]

  • 15. Anaplastic oligodendroglial tumors: a tale of two trials.
    Gilbert MR, Lang FF.
    J Clin Oncol; 2006 Jun 20; 24(18):2689-90. PubMed ID: 16782906
    [No Abstract] [Full Text] [Related]

  • 16. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PH, Idbaih A, Spliet WG, den Dunnen WF, Teepen JL, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, van den Bent MJ, French PJ.
    J Clin Oncol; 2013 Jan 20; 31(3):328-36. PubMed ID: 23269986
    [Abstract] [Full Text] [Related]

  • 17. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC, Gesme D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R.
    J Clin Oncol; 2003 Jan 15; 21(2):251-5. PubMed ID: 12525516
    [Abstract] [Full Text] [Related]

  • 19. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P, Wick W, Weller M.
    Curr Treat Options Oncol; 2013 Dec 15; 14(4):505-13. PubMed ID: 23907441
    [Abstract] [Full Text] [Related]

  • 20. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R, Nobile M, Rudà R, Borgognone M, Costanza A, Laguzzi E, Mutani R.
    Cancer; 2004 Feb 15; 100(4):807-13. PubMed ID: 14770438
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.